CD8A and neoplasm: In a lung tumor model, where cancers were driven by HPV16, IL-2 therapy in conjunction with Aza treatment caused dramatic CD8+ T cell infiltration, which was required for anti-tumor efficacy (54), similar to the latter results of our study.